{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:59:29Z","timestamp":1791939569822,"version":"4.3.4"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T00:00:00Z","timestamp":1591660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T00:00:00Z","timestamp":1591660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1007\/s40265-020-01339-3","type":"journal-article","created":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T12:03:04Z","timestamp":1591704184000},"page":"1027-1031","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":198,"title":["Viltolarsen: First Approval"],"prefix":"10.1007","volume":"80","author":[{"given":"Sohita","family":"Dhillon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,9]]},"reference":[{"issue":"7","key":"1339_CR1","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/s41582-019-0203-3","volume":"15","author":"IEC Verhaart","year":"2019","unstructured":"Verhaart IEC, Aartsma-Rus A. Therapeutic developments for Duchenne muscular dystrophy. Nat Rev Neurol. 2019;15(7):373\u201386.","journal-title":"Nat Rev Neurol"},{"key":"1339_CR2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/978-1-4939-8651-4_2","volume":"1828","author":"M Rodrigues","year":"2018","unstructured":"Rodrigues M, Yokota T. An overview of recent advances and clinical applications of exon skipping and splice modulation for muscular dystrophy and various genetic diseases. Methods Mol Biol. 2018;1828:31\u201355.","journal-title":"Methods Mol Biol"},{"key":"1339_CR3","unstructured":"US National Institutes of Health. Duchenne and Becker muscular dystrophy. 2020. https:\/\/ghr.nlm.nih.gov\/condition\/duchenne-and-becker-muscular-dystrophy#statistics. Accessed 21 May 2010."},{"key":"1339_CR4","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.coph.2017.04.002","volume":"34","author":"S Guiraud","year":"2017","unstructured":"Guiraud S, Davies KE. Pharmacological advances for treatment in Duchenne muscular dystrophy. Curr Opin Pharmacol. 2017;34:36\u201348.","journal-title":"Curr Opin Pharmacol"},{"issue":"3","key":"1339_CR5","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3390\/jpm3030144","volume":"3","author":"J Lee","year":"2013","unstructured":"Lee J, Yokota T. Antisense therapy in neurology. J Pers Med. 2013;3(3):144\u201376.","journal-title":"J Pers Med"},{"key":"1339_CR6","unstructured":"Komaki H, Takeshima Y, Matsumura T, et al. A Japanese phase I\/II study of NS-065\/NCNP-01, exon 53 skipping drug, in patients with Duchenne muscular dystrophy\u2014a dose-finding study [abstract no. P.129 and poster]. Neuromuscul Disord. 2018;28(Suppl 2):S68."},{"key":"1339_CR7","unstructured":"Nippon Shinyaku. Marketing authorization in Japan of VILTEPSO\u00ae intravenous infusion 250 mg for the treatment of Duchenne muscular dystrophy [media release]. 25 Mar 2020. https:\/\/www.nippon-shinyaku.co.jp\/file\/download.php?file_id=2965."},{"key":"1339_CR8","unstructured":"Nippon Shinyaku Co. Ltd. Viltepso\u00ae injection 250 mg: Japanese prescribing information. 2020. https:\/\/www.pmda.go.jp\/. Accessed 4 May 2020."},{"key":"1339_CR9","unstructured":"National Center of Neurology Psychiatry, Nippon Shinyaku Co. Ltd. Clinical study starts for the treatment of Duchenne muscular dystrophy: the first clinical study of an antisense oligonucleotide discovered in Japan [media release]. 9 May 2013. https:\/\/www.nippon-shinyaku.co.jp\/english\/company_profile\/news.php?id=932."},{"key":"1339_CR10","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.omtn.2018.09.017","volume":"13","author":"N Watanabe","year":"2018","unstructured":"Watanabe N, Nagata T, Satou Y, et al. NS-065\/NCNP-01: an antisense oligonucleotide for potential treatment of exon 53 skipping in Duchenne muscular dystrophy. Mol Ther Nucleic Acids. 2018;13:442\u20139.","journal-title":"Mol Ther Nucleic Acids"},{"key":"1339_CR11","unstructured":"Clemens P, Rao V, Connolly A, et al. A phase II, dose finding study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of NS-065\/NCNP-01 (viltolarsen) in boys with Duchenne muscular dystrophy (DMD) [abstract no. P.128 and poster]. Neuromuscul Disord. 2018;28(Suppl 2):S68."},{"key":"1339_CR12","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.1264","author":"PR Clemens","year":"2020","unstructured":"Clemens PR, Rao VK, Connolly AM, et al. Safety, tolerability, and efficacy of viltolarsen in boys with Duchenne muscular dystrophy amenable to exon 53 skipping: a phase 2 randomized clinical trial. JAMA Neurol. 2020. https:\/\/doi.org\/10.1001\/jamaneurol.2020.1264.","journal-title":"JAMA Neurol"},{"key":"1339_CR13","doi-asserted-by":"crossref","unstructured":"Komaki H, Nagata T, Saito T, et al. Systemic administration of the antisense oligonucleotide NS-065\/NCNP-01 for skipping of exon 53 in patients with Duchenne muscular dystrophy. Sci Transl Med. 2018;10(437).","DOI":"10.1126\/scitranslmed.aan0713"},{"key":"1339_CR14","doi-asserted-by":"crossref","unstructured":"Clemens P, Rao V, Connolly A, et al. Dystrophin restoration by exon 53 skipping in patients with Duchenne muscular dystrophy after viltolarsen treatment: phase 2 study update [abstract no. P.337]. Neuromuscul Disord. 2019;29(Suppl 1):S165-S6.","DOI":"10.1016\/j.nmd.2019.06.451"},{"key":"1339_CR15","unstructured":"Rao V, Connolly A, Zaidman C, et al. Dystrophin restoration by exon 53 skipping in patients with Duchenne muscular dystrophy after viltolarsen treatment: phase 2 study update [abstract no. 187]. Ann Neurol. 2019;86(Suppl 23):S128."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-020-01339-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-020-01339-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-020-01339-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T23:34:37Z","timestamp":1623195277000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-020-01339-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,9]]},"references-count":15,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["1339"],"URL":"https:\/\/doi.org\/10.1007\/s40265-020-01339-3","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,9]]},"assertion":[{"value":"9 June 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Sohita Dhillon is a contracted employee of Adis International Ltd\/Springer Nature, is responsible for the article content and declares no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}